Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients
Not Applicable
- Conditions
- chronic kidney disease
- Registration Number
- JPRN-UMIN000015671
- Lead Sponsor
- Department of Nephrology, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Allergy to ARB Liver dysfunction Pregnancy Inappropriate patients judged by their physiocians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in CKD biomarkers such as urinary protein, urinary L-FABP and renal hypoxia measured by BOLD-MRI, and CAVI as an arteriosclerosis biomarker
- Secondary Outcome Measures
Name Time Method